Key result
In vitro adrenaline supplementation increased median ADP-induced platelet aggregation from 15 to 26 units and active fibrinogen receptor binding from 40% to 83% in ticagrelor-treated patients.
Why the study?
Does in vitro adrenaline supplementation improve ADP-induced platelet aggregation and activation in blood samples from ACS patients on ASA and ticagrelor?
Does in vitro adrenaline supplementation improve ADP-induced platelet aggregation and activation in blood samples from ACS patients on ASA and ticagrelor?
Absolute Event Rate: 26% vs 15%
In vitro adrenaline supplementation enhances platelet aggregation and activation in blood from ticagrelor-treated ACS patients, suggesting a potential strategy for managing bleeding or urgent surgery.
May augment residual platelet reactivity on ticagrelor; hypothesis-generating and should not yet change practice.
BACKGROUND: -receptors on platelets and potentially enhance platelet reactivity. OBJECTIVE: To assess if adrenaline can improve adenosine diphosphate (ADP)-induced platelet aggregation and activation in blood samples from patients on dual antiplatelet therapy with acetylsalicylic acid (ASA) and the ADP-receptor antagonist ticagrelor. METHODS: Blood samples were collected from a total of forty acute coronary syndrome patients on dual antiplatelet therapy with ASA and ticagrelor. ADP-induced platelet aggregation (by impedance aggregometry) and activation (by flow cytometry) were assessed before and after supplementation with adrenaline and/or platelet concentrate. RESULTS: ) increased median ADP-induced aggregation from 15 (25-75th percentiles: 10-20) to 26 (18-38) aggregation units. The effect was independent of concomitant platelet supplementation. Adrenaline also increased ADP-induced platelet activation: from 40% (36-54%) to 83% (74-88%) platelets with active fibrinogen receptor (binding PAC-1) and from 13% (7-21%) to 35% (18-50%) P-selectin-expressing platelets. CONCLUSIONS: Adrenaline potentiated ADP-induced platelet aggregation and activation in blood samples from ticagrelor-treated patients. Adrenaline infusion may be a new method to enhance platelet function in ticagrelor-treated patients who are in need of acute surgery or have ongoing bleeding. In vivo studies are needed to confirm the present results.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2018) studied Acute coronary syndrome (n=40). Adrenaline vs. Before supplementation was evaluated on ADP-induced platelet aggregation. In vitro adrenaline supplementation increased median ADP-induced platelet aggregation from 15 to 26 units and active fibrinogen receptor binding from 40% to 83% in ticagrelor-treated patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: